Cardiometabolic Syndrome
The cardiometabolic syndrome is a highly prevalent (though under-recognized and undertreated) condition significantly contributing to the development and progression of the number one cause of death in the U.S.—atherosclerotic cardiovascular disease. While the construct is undergoing some discussion regarding its true definition, the cardiometabolic syndrome is widely seen as an indicator for early and aggressive intervention. This condition involves the concurrence of type 2 diabetes (or borderline hyperglycemia), abdominal obesity, atherogenic lipoprotein phenotype, a pro-coagulant state, and/or hypertension constituting a system of linked pathogenesis and high atherogenicity.
The Joslin Cardiometabolic Forum were symposia consisting of didactic lectures and case discussions presented on a weekend morning in five metropolitan areas across the U.S. Register here to participate in a CME-certified Internet enduring material developed from these symposia.


Already a member
Professional Education Members
If you are already a registered member of Joslin Professional Education, use your email address and password here.

  Forgot your password?

 
 
Register as a new member
Choose a password (minimum of 6 characters) and register
*All fields required

 
This activity is supported through an educational grant provided by Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; and Takeda Pharmaceuticals North America, Inc., with additional grant support provided by sanofi-aventis U.S. LLC and Pfizer Inc.